Replimune (REPL) Non-Current Deffered Revenue (2018 - 2019)
Replimune (REPL) posted Non-Current Deffered Revenue of $24000.0 for Q1 2019, down 85.71% sequentially from $168000.0 in Q4 2018, and down 53.85% YoY from $52000.0 in Q1 2018.
Replimune (REPL) Non-Current Deffered Revenue (2018 - 2019) Analysis & Trends
Replimune has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $24000.0 in Q1 2019.
- Quarterly Non-Current Deffered Revenue fell 53.85% year-over-year to $24000.0 in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $24000.0 (down 53.85% YoY) and the FY2019 annual result came in at $24000.0, down 53.85% from the prior year.
- Non-Current Deffered Revenue eased to $24000.0 in Q1 2019 per REPL's latest filing, from $168000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $168000.0 in Q4 2018 and troughed at $24000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 24,000.00 |
| Dec 31, 2018 | 168,000.00 |
| Sep 30, 2018 | 36,000.00 |
| Jun 30, 2018 | 43,000.00 |
| Mar 31, 2018 | 52,000.00 |